Teladoc Health Reports Q1 Revenue Decline to $613.85M, EPS Loss Narrows to ($0.36)
TDOC sits 22% above its 52-week low of $4.4.
Summary
Teladoc Health reported Q1 2026 revenue of $613.85 million, a 2.5% year-over-year decline, with its BetterHelp segment revenue falling 9%. Despite the revenue dip, the company significantly narrowed its net loss to $63.84 million (from $93.01 million) and improved diluted EPS to ($0.36) from ($0.53) in the prior year. This official 10-Q summary confirms and quantifies the Q1 revenue decline that was initially reported by Reuters yesterday, providing the full financial details. The continued revenue decline, particularly in the BetterHelp segment, is a concern for growth, but the substantial improvement in profitability suggests effective cost management and restructuring efforts. Investors will monitor whether restructuring efforts can reverse the revenue decline in future quarters while maintaining profitability improvements.
At the time of this announcement, TDOC was trading at $5.39 on NYSE in the Technology sector, with a market capitalization of approximately $972.5M. The 52-week trading range was $4.40 to $9.77. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.